Intravenous azithromycin

Annals of Pharmacotherapy

Volumn 33, Issue 2, 1999, Pages 218-228

  Garey, Kevin W ^a   Amsden, Guy W ^b  

^a BASSETT HEALTHCARE   (United States)

^b BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

Azalides; Intravenous azithromycin; Macrolides

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CEFOXITIN; CEFTRIAXONE; CEFUROXIME; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; METRONIDAZOLE; PROBENECID; UNCLASSIFIED DRUG; ZITHROMAX IV;

ADVERSE DRUG REACTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; CLINICAL TRIAL; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TOLERABILITY; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PELVIC INFLAMMATORY DISEASE; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CLINICAL TRIALS; COMMUNITY-ACQUIRED INFECTIONS; DRUG INTERACTIONS; DRUG RESISTANCE, MICROBIAL; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MEDLINE; PELVIC INFLAMMATORY DISEASE; PNEUMONIA, BACTERIAL;

EID: 0032981522     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18046     Document Type: Review

References (60)

1. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992;26:1253-61.
2. Peters DH, Friedel HA, McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992;44:750-99.
3. Data on file, Pfizer, Inc., New York, NY.
4. Retsema J, Girard A, Schelky W, Manousos M, Anderson M, Bright G. et al. Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 1987;31:1939-47.
5. Li Z, Hancock REW. Mechanism of uptake of the dibasic macrolide antibiotic azithromycin across the outer membrane of Escherichia coli (abstract). Proceedings of the 6th International Congress of Infectious Diseases, Montreal, Quebec, Canada, July 1990.
6. Goldman RC, Fesid SW, Doran CC. Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 1990;34:426-31.
7. Rice RJ, Bhullar V, Mitchell SH, Bullard J, Knapp JS. Susceptibilities of Chlamydia trachomatis isolates causing uncomplicated female genital tract infections and pelvic inflammatory disease. Antimicrob Agents Chemother 1995;39:760-2.
8. Hardy DJ, Hensey DM, Beyer JM, Vojtko C, McDonald EJ, Fernandes PB. Comparitive in vitro activities of new 14-,15-, and 16-membered macrolides. Antimicrob Agents Chemother 1988:32:1710-9.
9. Barry AL, Pfaller MA, Fuchs PC, Packer RR. In vitro activities of 12 orally administered antimicrobial agents against four species of bacterial respiratory pathogens from US medical centers in 1992 and 1993. Antimicrob Agents Chemother 1994;38:2419-25.
10. Nimmo GR, Bull JZ. Comparative susceptibility of Legionella pneumophila and Legionella longbeachae to 12 antimicrobial agents. J Antimicrob Chemother 1995;36:219-23.
11. Roblin PR, Sokolovskaya N, Hammerschlag MR. Susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from patients with community acquired pneumonia (abstract). In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology: Washington, DC, 1995:83.
12. Ishida K, Kaku M, Irifune K, Mizukane R, Takemura H, Yoshida R. et al. In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae. Antimicrob Agents Chemother 1994;38:790-8.
13. Rylander M, Hallander HO. In vitro comparison of the activity of doxycycline, tetracycline, erythromycin, and a new macrolide, CP 62993, against Mycoplasma pneumoniae. Mycoplasma hominis, and Ureaplasma urealyticum. Scand J Infect Dis 1988;53(suppl):12-7.
14. Renaudin H, Bebear C. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin, and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum. Eur J Clin Microbiol Infect Dis 1990;9:838-41.
15. Neu HC. Clinical microbiology of azithromycin. Am J Med 1991:91 (suppl3A):12S-18S.
16. Dunn CJ, Barradell LB. Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections. Drugs 1996;51:483-505.
17. Doern GV, Brueggemann A, Holley HP, Rauch AM. Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrob Agents Chemother 1996; 40:1208-13.
18. Ballow CH, Jones RN, Johnson DM, Schentag JJ, the SPAR study group. Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis 1997;29:173-86.
19. LeClerq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramins antibiotics in bacteria. Antimicrob Agents Chemother 1991;35:1273-6.
20. Moellering RC. Introduction: revolutionary changes in the macrolide and azalide antibiotics. Am J Med 1991;91(suppl 3A)1S-4S.
21. Weisblum B. Inducible resistance to macrolides, lincosamides, and streptogramins type B antibiotics: the resistance phenotype, its biological diversity and structural elements that regulate expression - a review. J Antimicrob Chemother 1985;16(suppl A):63-90.
22. Wondrack L, Massa M, Yang BV, Sutcliffe J. Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides. Antimicrob Agents Chemother 1996;40:992-8.
23. Gerardo SH, Citron DM, Claros MC, Goldstein JC. Comparison of Etest broth microdilution method for testing Streptococcus pneumoniae susceptibility to levofloxacin and three macrolides. Antimicrob Agents Chemother 1996;40:2413-5.
24. Thakker KM, Caridi F, Powell M, Kolokathis A, Chung M. Multiple-dose pharmacokinetics of azithromycin following 1-hour intravenous infusions in hospitalised patients with community-acquired pneumonia (abstract). In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology. Toronto, Ontario, Canada, 1997.
25. Luke DR, Foulds G, Cohen SF, Levy B, Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob Agents Chemother 1996;40:2577-81.
26. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25 (suppl A):73-82.
27. Olsen KM, San Pedro SG, Gann LP, Gubbins PO, Halinski DM, Campbell GC Jr. Intrapulmonary pharmacokinetics of azithromycin in healthy volunteers given five oral doses. Antimicrob Agents Chemother 1996; 40:2582-5.
28. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62.993) by phagocytic cells: possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989;33:1056-60.
29. Laufen H, Wildfeuer A, Lach P. Mechanism of azithromycin uptake in human polymorphonuclear leucocytes. Arzneimittelforschung 1990;40: 686-9.
30. Wildfeuer A, Laufen H, Muller-Wening D, Haferkamp O. Interaction of azithromycin and human phagocytic cells. Uptake of the antibiotic and the effect on the survival of ingested bacteria in phagocytes. Arzneimittelforschung 1989;39:755-68.
31. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997;16:438-43.
32. Ballow CH, Amsden GW, Highet VS, Forrest A. Healthy volunteer pharmacokinetics of oral azithromycin in serum, urine, polymorphonuclear leukocytes and inflammatory vs. non-inflammatory skin blisters. Clin Drug Invest 1998;15:159-67.
33. Shephard RM, Fouda HG, Ferraina RA, Mullins MA. Disposition and metabolism of azithromycin in rats, dogs and humans (abstract). Proceedings of the 6th International Congress of Infectious Diseases, Montreal, Quebec, Canada, July 1990.
34. Luke DR, Foulds G. Disposition of oral azithromycin in humans. Clin Pharmacol Ther 1997;61:641-8.
35. Mazzei T, Surrenti C, Novelli A, Crispo A, Fallani S. Pharmacokinetics of azithromycin in patients with impaired hepatic function (abstract). Proceedings of the Mediterranean Congress of Chemotherapy, Athens, Greece, May 1992.
36. Schentag JJ, Ballow CH. Tissue directed pharmacokinetics. Am J Med 1991;91(suppl A):5-11.
37. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991:10:807-12.
38. Vergis EN, Phillips J, Bates JH, File TM, Tan JS, Sarosi GA, et al. A prospective, randomized, multicenter trial of azithromycin versus cefuroxime plus erythromycin for community-acquired pneumonia in hospitalized patients (abstract). 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, CA, September 1997.
39. Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
40. Bohte R, van't Wout JW, Lobatto S, Blusse van Oud AA. Beokhout M, Nauta EH, et al. Efficacy and safety of azithromycin versus benzylpenicillin or erythromycin in community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 1995;14:182-7.
41. Dorrell L, Fulton B, Ong ELC. Intravenous azithromycin as salvage therapy in a patient with Legionnaire's disease. Thorax 1994;49:620-1.
42. Stout JE, Yu VL, Legionellosis. N Engl J Med 1997;337:682-7.
43. Wiselka MJ, Read R, Finch RG. Response to oral and intravenous azithromycin in a patient with toxoplasma encephalitis and AIDS. J Infect 1996;33:227-9.
44. Kelsey JJ, Moser LR, Jennings JC, Munger MA. Presence of azithromycin breast milk concentrations: a case report. Am J Obstet Gynecol 1994;170:1375-6.
45. Luke DR, Foulds G, Friedman HL, Going PC, Scavone J, Curatolo WJ. Site-specific toleration and adsorption of azithromycin. In: Proceedings of the 3rd International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portugal, January 24, 1996.
46. Sana JR, Butler VP Jr. Neu HC, Lindenbaum J. Digoxin-inactivating bacteria: identification in human gut flora. Science 1983;220:325-7.
47. Zimmerman T, Yeates RA, Laufen H, Scharpf F, Leitold M, Wildfeuer A. Influence of antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 1996;46:213-7.
48. Yeates RA, Laufen H, Zimmerman T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996;34:400-5.
49. Nahata M. Drug interactions with azithromycin and the macrolides: an overview. J Antimicrob Chemother 1996;37(suppl C): 133-42.
50. Amsden GW. Macrolides versus azalides: a drug interaction update. Ann Pharmacother 1995;29:906-17.
51. Harris S, Hilligoss DM, Colangelo PM, Eller M, Okerholm R. Azithromycin and terfenadine: lack of drug interaction. Clin Pharmacol Ther 1995;58:310-5.
52. Devereaux A, Murray K, Mahon R, Dennen MT. A58 The effect of azithromycin on serum theophylline levels during acute respiratory tract infections in COPD. Am J Respir Crit Care Med 1998;157:A166.
53. Pollak PT, Slayter KL. Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction. Pharmacotherapy 1997;17:827-9.
54. Granden JW, Fisher KA. Lovastatin-induced rhahdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997;31:859-63.
55. Lane G. Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin (letter). Ann Pharmacother 1996;30:884-5.
56. Ljutic D, Rumboldt Z. Possible interaction between azithromycin and cyclosporin: a case report. Nephron 1995;70:130.
57. Zimmerman T, Riedel KD, Laufen H, Treadway G, Liu J, Wildfeuer A. Intravenous toleration of azithromycin in comparison to clarithromycin and erythromcyin (abstract). In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, San Franciso, CA, 1996.
58. Luke DR, Foulds G. Toleration of intravenous azithromycin. Ann Pharmacother 1997;31:965-9.
59. McDonald PJ, Pruul H. Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 1991;10:1-6.
60. 1997 Drug topics red book and updates. Montvale, NJ: Medical Economics, 1997.